EMGALITY (galcanezumab-gnlm) injection, for subcutaneous use. EMGALITY® is a calcitonin-gene related peptide Antagonist indicated in adults for the • preventive treatment of migraine. • treatment of episodic cluster headache.
"• Injection: 120 mg/mL solution in a single-dose prefilled pen (3)
• Injection: 120 mg/mL solution in a single-dose prefilled syringe (3)
• Injection: 100 mg/mL solution in a single-dose prefilled syringe"
"• For subcutaneous use only.
• Migraine recommended dosage: 240 mg loading dose (administered as two consecutive injections of 120 mg each),
followed by monthly doses of 120 mg.
• Episodic cluster headache recommended dosage: 300 mg (administered as three consecutive injections of 100 mg each) at the onset of the cluster period, and then monthly until the end of the cluster period.
• Administer in the abdomen, thigh, back of the upper arm, or buttocks subcutaneously."
• Migraine
• Episodic cluster headache
